Acanthosis nigricans (AN) is a skin condition characterised by velvety, thickened, hyperpigmented patches — most commonly on the posterior and lateral neck, axillae (underarms), groin folds, and knuckles. The texture is distinctly different from ordinary pigmentation: it is raised, soft, and velvety rather than flat. The affected skin may also have a slightly warty surface in more advanced cases.
It is not a cosmetic condition in the primary sense — it is a cutaneous marker of metabolic, hormonal, or systemic pathology. The skin change is driven by elevated insulin or insulin-like growth factor levels stimulating keratinocyte and fibroblast proliferation in the skin. Treating the patches without addressing the driver is comparable to treating a fever without treating the infection causing it.
| Cause type | Mechanism | Most common in | Treatment priority |
|---|---|---|---|
| Insulin resistance | Excess insulin stimulates skin cell proliferation | Obesity, type 2 diabetes, metabolic syndrome | Address insulin resistance — weight loss, metformin, diet |
| PCOD (PCOS) | Hyperinsulinaemia from androgen-insulin interaction drives AN | Women of reproductive age; very common in Kota patients | PCOD management alongside cosmetic treatment |
| Drug-induced | Certain medications cause AN as a side effect | Patients on nicotinic acid, glucocorticoids, oral contraceptives | Discontinue suspected drug where possible |
| Hereditary | Genetic predisposition without metabolic cause | Family history; often presents in childhood | May stabilise spontaneously; cosmetic treatment for patches |
| Malignant (rare) | Paraneoplastic — internal tumour secreting growth factors | Sudden onset in adults without metabolic risk factors; rapid spread | Urgent investigation — this is a red flag presentation |
The most common cause of acanthosis nigricans in female patients at Skinssence is PCOD. PCOD-driven hyperandrogenism leads to compensatory hyperinsulinaemia — elevated insulin levels that directly stimulate the skin cell proliferation that produces AN patches. The skin change on the neck and underarms is often one of the first visible signs that insulin resistance is developing in a PCOD patient.
In these patients, treating only the skin patches with topical agents produces gradual and partial improvement that reverses when treatment stops — because the hormonal driver continues. The most clinically effective approach is PCOD management (metformin, hormonal regulation, weight normalisation) alongside the cosmetic skin treatment. When insulin levels reduce, the AN patches reduce significantly — sometimes without any topical treatment at all.
Treatment outcomes depend almost entirely on the underlying cause:
The texture improvement (velvety thickening reducing) typically precedes colour improvement — patients often notice patches becoming flatter before they become lighter. Both changes are signs of treatment working.
Yes — when the underlying cause is treated. In patients with insulin resistance or PCOD who achieve metabolic improvement through weight loss, diet, or medication, AN patches reduce significantly and often resolve over 6–12 months. In drug-induced cases, resolution follows drug withdrawal. In hereditary cases, complete resolution is less predictable but partial improvement is achievable with consistent treatment. See: PCOD treatment at Skinssence →
OTC keratolytic products (salicylic acid body wash, lactic acid lotions) produce mild surface improvement in early or mild patches. They cannot address the hyperkeratotic thickening of established AN and have no effect on the underlying metabolic cause. Prescription topical retinoids are significantly more effective and require a dermatologist assessment before starting — tretinoin concentrations and application frequency need to be calibrated to your skin's tolerance. Home treatment without investigating the cause is not appropriate if AN patches are new, worsening, or extensive.
In rare cases — yes. Malignant acanthosis nigricans is a paraneoplastic condition where internal tumours secrete growth factors that drive the skin change. The clinical features that distinguish it from metabolic AN: sudden onset in an adult without obesity or metabolic risk factors, rapid spread to atypical areas (lips, palms, oral mucosa), and associated weight loss. This presentation requires urgent investigation. The overwhelming majority of AN cases are metabolic or hormonal — but sudden unexplained onset warrants dermatologist evaluation rather than self-diagnosis.
PCOD drives hyperandrogenism, which causes compensatory hyperinsulinaemia — elevated insulin directly stimulates the skin cell proliferation that produces AN patches on the neck, underarms, and groin. AN is one of the most visible skin signs of insulin resistance developing in a PCOD patient. Treating only the skin without managing the PCOD produces temporary improvement. The most effective approach combines PCOD hormonal management with topical or procedural skin treatment. See: PCOD treatment at Skinssence →
Topical retinoids require 8–12 weeks of consistent use for visible improvement. Chemical peel courses show improvement across 4–6 sessions. Metabolic improvement from weight loss or PCOD management produces gradual patch reduction over 6–12 months. Texture improvement (patches becoming less raised and velvety) typically appears before colour improvement. Patients on combined metabolic + topical + procedural treatment see the most consistent results.
Related: PCOD treatment at Skinssence → · Pigmentation treatment → · Chemical peels → · Laser skin toning → · About Dr. Ashima Madan →